iECURE is a clinical-stage biotechnology company developing genome editing therapies for rare, life-threatening genetic diseases, focusing on neurometabolic disorders and utilizing a variant-agnostic, in vivo targeted gene insertion strategy
iECURE is a clinical-stage biotechnology company developing genome editing therapies for rare, life-threatening genetic diseases, focusing on neurometabolic disorders and utilizing a variant-agnostic, in vivo targeted gene insertion strategy.